Sonoma Pharmaceuticals Reports Q2 Revenue Growth of 28% with Minimal GAAP Loss
Sonoma Pharmaceuticals (NASDAQ: SNOA) has released its second-quarter financial results, reporting revenue of $7.17 million. This represents a significant year-over-year increase of 28.0%, signaling strong top-line growth for the company. Despite the revenue surge, the company reported a GAAP earnings per share (EPS) of -$0.01. While the company remains slightly unprofitable on a GAAP basis, the narrowness of the loss relative to the substantial revenue growth suggests an improving financial trajectory.
Tickers: $SNOA
Topics: earnings GAAP EPS revenue growth
Read the full article at Seeking Alpha
Part of the story Flint Reports Q3 Revenue Growth of 79.6% to C$267.22M (7 articles)